OBJECTIVES: In this study, we evaluated the cellular origins and thrombogenic potential of microparticles. BACKGROUND: Human atherosclerotic plaques contain submicron vesicles (microparticles) released during cell activation or apoptosis. METHODS: Microparticles were purified from plaques and platelet-free plasma from 26 patients undergoing carotid endarterectomy. Flow cytometry analysis revealed the presence of large amounts of microparticles in plaques but not in healthy vessels. RESULTS: Most plaque microparticles originated from leukocytes, of which 29 +/- 5% were macrophages, 15 +/- 3% lymphocytes, and 8 +/- 1% granulocytes. Plaques microparticles also derived from erythrocytes (27 +/- 4%), smooth muscle (13 +/- 4%) and endothelial cells (8 +/- 2%), but not from platelets. Plaques from asymptomatic and symptomatic patients showed no differences in microparticle origins. Microparticles were at least 200-fold more concentrated in plaque than in plasma. Plasma microparticles were primarily platelet-derived in contrast with those of plaque and showed no smooth muscle cell origin. Both plaque and plasma microparticles exposed tissue factor and generated thrombin, but this activity was twice as high in microparticles isolated from plaques, reflecting the thrombogenic contribution of the individual classes of microparticles. CONCLUSIONS: These results demonstrate that microparticles are more abundant and more thrombogenic in human atherosclerotic plaques than in plasma. The different cellular origins of plaque and plasma microparticles might explain the increased thrombogenic activity of plaque microparticles.
OBJECTIVES: In this study, we evaluated the cellular origins and thrombogenic potential of microparticles. BACKGROUND:Humanatherosclerotic plaques contain submicron vesicles (microparticles) released during cell activation or apoptosis. METHODS: Microparticles were purified from plaques and platelet-free plasma from 26 patients undergoing carotid endarterectomy. Flow cytometry analysis revealed the presence of large amounts of microparticles in plaques but not in healthy vessels. RESULTS: Most plaque microparticles originated from leukocytes, of which 29 +/- 5% were macrophages, 15 +/- 3% lymphocytes, and 8 +/- 1% granulocytes. Plaques microparticles also derived from erythrocytes (27 +/- 4%), smooth muscle (13 +/- 4%) and endothelial cells (8 +/- 2%), but not from platelets. Plaques from asymptomatic and symptomatic patients showed no differences in microparticle origins. Microparticles were at least 200-fold more concentrated in plaque than in plasma. Plasma microparticles were primarily platelet-derived in contrast with those of plaque and showed no smooth muscle cell origin. Both plaque and plasma microparticles exposed tissue factor and generated thrombin, but this activity was twice as high in microparticles isolated from plaques, reflecting the thrombogenic contribution of the individual classes of microparticles. CONCLUSIONS: These results demonstrate that microparticles are more abundant and more thrombogenic in humanatherosclerotic plaques than in plasma. The different cellular origins of plaque and plasma microparticles might explain the increased thrombogenic activity of plaque microparticles.
Authors: Zheng Qin; Ruoxi Liao; Yuqin Xiong; Luojia Jiang; Jiameng Li; Liya Wang; Mei Han; Si Sun; Jiwen Geng; Qinbo Yang; Zhuyun Zhang; Yupei Li; Heyue Du; Baihai Su Journal: Ann Transl Med Date: 2021-04
Authors: Virginia M Miller; Vesna D Garovic; Kent R Bailey; Brian D Lahr; Michelle M Mielke; Wendy M White; Muthuvel Jayachandran Journal: Atherosclerosis Date: 2016-09-09 Impact factor: 5.162
Authors: Andrea Caporali; Elisabetta Pani; Anton J G Horrevoets; Nicolle Kraenkel; Atsuhiko Oikawa; Graciela B Sala-Newby; Marco Meloni; Brunella Cristofaro; Gallia Graiani; Aurelie S Leroyer; Chantal M Boulanger; Gaia Spinetti; Sung Ok Yoon; Paolo Madeddu; Costanza Emanueli Journal: Circ Res Date: 2008-06-19 Impact factor: 17.367
Authors: Virginia M Miller; Larry W Hunter; Kevin Chu; Vivasvat Kaul; Phillip D Squillace; John C Lieske; Muthuvel Jayachandran Journal: Nanomedicine (Lond) Date: 2009-10 Impact factor: 5.307
Authors: Sanja Jelic; David J Lederer; Tessa Adams; Margherita Padeletti; Paolo C Colombo; Phillip Factor; Thierry H Le Jemtel Journal: Vasc Health Risk Manag Date: 2009-11-16
Authors: Caroline Bonner; Siobhán Bacon; Caoimhín G Concannon; Syed R Rizvi; Mathurin Baquié; Angela M Farrelly; Seán M Kilbride; Heiko Dussmann; Manus W Ward; Chantal M Boulanger; Claes B Wollheim; Rolf Graf; Maria M Byrne; Jochen H M Prehn Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: Birgit A Steppich; Siegmund Lorenz Braun; Andreas Stein; Gabriele Demetz; Philip Groha; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati; Ilka Ott Journal: Thromb J Date: 2009-07-02